Palo Alto, CANCT07022405Now EnrollingIRB Ready

Depression - Major Depressive Disorder Clinical Trial in Palo Alto, CA

Access cutting-edge depression - major depressive disorder treatment through this phase 2 clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Stanford University

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access depression - major depressive disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related depression - major depressive disorder treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this depression - major depressive disorder clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Depression - Major Depressive Disorder Study in Palo Alto

This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition. Eligible participants will undergo an 8-week treatment course of pramipexole followed by a 2-week down taper and follow up. The ultimate goal is to offer people experiencing depression a medication that is alternative to ones that may not have worked in the past and to apply the knowledge the investigators gain from investigating the brain circuits involved in depression to help personalize treatment. The investigators invite anyone who has recently experienced symptoms of depression to participate. A prior diagnosis of depression is not required.

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

18-65 years old (inclusive)
Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions.
Willing to provide written, informed consent.
Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI).
Patient Health Questionnaire-8 (PHQ-8) \>/= 10
Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI)

Exclusion Criteria

Suicidality with active plan or as determined clinician judgment
Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment
Severe impediment to vision, hearing, and/or hand movement likely to interfere with ability to complete the assessments, or is unable and/or unlikely to follow the study protocols as determined by clinician judgment
Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study
History of non-responsive depression to dopamine agonists
Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning
Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment
Previous or current diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder
Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months
Clinically significant presence/history of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months.
Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.)
Concurrent participation in other intervention or treatment studies

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT07022405) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Depression - Major Depressive Disorder Treatment Options in Palo Alto, CA

If you're searching for depression - major depressive disorder treatment options in Palo Alto, CA, this clinical trial (NCT07022405) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced depression - major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all depression - major depressive disorder clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Palo Alto, CA

See all depression clinical trials recruiting in Palo Alto — not just this study.

Browse Depression Trials in Palo Alto →

Browse More Trials by Condition

Depression TrialsMajor Depressive Disorder TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA